PCSK9 Inhibitor
The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives
Supported by an educational grant from Novo Nordisk
Long-term PCSK9 inhibition plus background therapy improves LDL goal attainment in FH
Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported.
EPIC-STEMI
Treatment effect of the PCSK9 inhibitor alirocumab (Praluent, Sanofi/Regeneron) vs. sham control on LDL in patients with STEMI referred for primary PCI.
Optimizing Lipid Lowering Therapy in Women: Gaps Perspectives and Advances
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Residual CVD risk varies; individualized treatments best to combat it
BOSTON — The medical community is better equipped to combat residual CVD risk than previously, but prevention of residual risk should be tailored using a precision medicine approach, a speaker said at the Cardiometabolic Health Congress.
Familial hypercholesterolemia in 9% of young adults with ACS; many undertreated afterward
Among younger patients with ACS, approximately one in 11 had familial hypercholesterolemia, researchers reported in The American Journal of Cardiology.
Lipid-lowering therapy intensification low among veterans after MI, revascularization
Fewer than half of veterans, most of whom were not on lipid-lowering therapy before an event, received intensified lipid-lowering therapies after an MI or elective revascularization, researchers reported.
FOURIER-OLE
Long-term safety of evolocumab (Repatha, Amgen) in FOURIER participants.
Despite recommendations, statin use ‘not ubiquitous’ in CKD with ASCVD
Overall statin use among adults with chronic kidney disease is high, yet there have been only modest increases in the use of high‐intensity statins, ezetimibe and PCSK9 inhibitors, data from a prospective 2‐year study show.